Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jan 15, 2023 8:04pm
162 Views
Post# 35224594

RE:RE:RE:RE:Pfizer acquired preclinical Trillium for US$ 2.3 Bln

RE:RE:RE:RE:Pfizer acquired preclinical Trillium for US$ 2.3 BlnJanuary 13, 2023 - From Forbes Review of the story contained in the newly release novel entitled " For Blood and Money " subtitled " Billionaires, Biotech, and the Quest for a Blockbuster Drug" comes that following 

"Rothbaum grew amazed with how the human body worked. He marveled at the connections and mechanisms, the chain reactions and the interconnectedness of everything. He looked at the body as an elegant biomechanical machine made up of parts, molecular gears, cogs and switches that could be turned on or off. This machine followed rules defined by a genetic code and electrical pathways."


https://www.forbes.com/sites/nathanvardi/2023/01/13/for-blood-and-money-book-excerpt-wayne-rothbaum-pharmacyclics-robert-duggan/?sh=4ad0a7ea4f97

[ And how the body respondes to pelareop is why ONCY's Immune Molecule Platfrom Technology pelareorep is such an elegant therapy as demonstrated in it's molecular interactions with the tumor microenvironment  (TME)and the innate and adaptive immune system to facilitate its effective combination with current I/O agents for the synergistic treatment of multiple cancers ]
<< Previous
Bullboard Posts
Next >>